Beta Amyloid News and Research

RSS

Direct-to-Consumer Blood Test for Assessing User’s Alzheimer’s Disease Risk

In July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market. The test, which has not undergone Food and Drug Administration (FDA) review, measures the level of a protein called beta amyloid, a key component of plaques that form in the brains of Alzheimer’s disease patients, disrupting brain function.

23 Aug 2023

Study shows why “the brain's memory center” is vulnerable to damage, degeneration

In a world first, scientists from the University of Sussex have recorded blood oxygen levels in the hippocampus and provided experimental proof for why the area, commonly referred to as 'the brain's memory center', is vulnerable to damage and degeneration, a precursor to Alzheimer's disease.

31 May 2021

Tau protein in Alzheimer's disease looks different at every dementia stage

Research into Alzheimer's disease has long focused on understanding the role of two key proteins, beta amyloid and the tau protein. Found in tangles in patients' brain tissue, a pathological form of the tau protein contributes to propagating the disease in the brain.

19 Nov 2020